MultiplexDX

Pavol is an innovative leader with over 15 years of experience at the top research and government institutions. He received his doctorate in chemistry from the University of Iceland in 2009. As a Postdoctoral Associate at Rockefeller University, Pavol developed methodology for the retention of nucleic acids in tissue sections during RNA in situ hybridization and preparation/validation of specific oligonucleotide probes and fluorescent signal amplification processes.

Before founding MultiplexDX, he was working at a premier cancer research organization - National Cancer Institute (NCI) for 4 years. Pavol is a PhD trained Nucleic Acid Chemist/Biochemist focusing on modified oligonucleotide synthesis and spectroscopic analysis of nucleic acid structure/function.

Pavol has 35+ scientific publications, is the inventor of 3 granted patents, and is a member of the Science Advisory Board of the Slovakian Ministry of Health. Pavol is a member of an exclusive network of CEOs called Mindshare and won several prestigious awards highlighting his business and scientific achievements.

For 7 years, Peter worked as a Biotechnology consultant at Neulogy, a market leader in providing complex consulting and incubation services to research institutes and entrepreneurs in all parts of Slovakia. Peter was also a Managing Director at BioScience Slovakia, a biotechnology company focused on development of innovative diagnostics and treatment tools in the area of cancer and virology.

Peter is experienced in technology transfer, conception and implementation of projects funded by EU structural funds, topics he addressed while working as Managing Director at BioScience Slovakia. He is an EPO certified trainer in the field of intellectual property. Peter studied Biomedical physics at Comenius University in Bratislava and since 2005 holds a PhD in Physiology and Biophysics from Université de Sherbrooke in Canada.

Petra received her Master of Science degree (Ecology and Environmental Sciences) from Technical University of Zvolen in 1999. She has over 15 years of executive and management experience in European projects aimed at enhancing the R&D infrastructure in Slovakia and other R&D projects.

She specializes in management of R&D, technology commercialization, tech transfer, start-ups, fundraising and science communication. She is also the architect of a national science festival with ca. 180K visitors in a single day. Petra is a former Chairwoman and CEO of Neulogy, innovation boutique consultancy (now part of Civitta Group). For many years, Petra managed and executed Neulogy‘s mission to help start-ups, companies, academic institutions and research centers to conduct world class R&D projects as well as having access to financing from both public and private sources, including seed and venture capital. She is a Chairwoman of the Board at the Slovak Organization for Research and Development Activities, an NGO supporting the research ecosystem in Slovakia.

Evan is a dynamic biomedical scientist with over 15 years of experience conducting research in molecular biology and analytical chemistry, with an emphasis on discovering novel biomarkers and therapeutic targets.

He received a dual PhD in Integrative Physiology and Neuroscience from the University of Colorado Boulder, USA, where he directed an analytical chemistry core unit to detect small molecule neurotransmitters in the brain. He also received a minor degree in Business Administration. He continued his research as a postdoc in Alon Chen’s prestigious laboratory jointly sponsored by the Max Planck Institute of Psychiatry in Munich, Germany and the Weizmann Institute of Science in Rehovot, Israel. There he developed protocols using next generation sequencing and in situ hybridization to quantify and visualize, respectively, microRNAs in order to identify novel biomarkers for psychiatric disorders.

He has published 25+ scientific papers and book chapters in prestigious journals like Nature Neuroscience and Neuron, with the latter resulting in a patent for a novel microRNA biomarker for depression that was licensed to miCure therapeutics Ltd.

Peter is a senior finance executive, and board member with strong commercial acumen and tangible accomplishments across diverse pharmaceutical markets both in Europe and Asia.

During his 18 years tenure with Novartis, one of the global pharmaceutical leaders, he spearheaded worldwide finance operations of a multi-billion enterprise, led publicly listed entities as well as commercial operations in the most complex markets.

Heading Business Development and Licensing operations, he has been consistently recognized for designing and executing innovative external collaborations and transformative deals. Before Novartis, he spent several years in various advisory and consultancy roles with blue-chip companies in Europe.

‍

Pavol is an innovative leader with over 15 years of experience at the top research and government institutions. He received his doctorate in chemistry from the University of Iceland in 2009. As a Postdoctoral Associate at Rockefeller University, Pavol developed methodology for the retention of nucleic acids in tissue sections during RNA in situ hybridization and preparation/validation of specific oligonucleotide probes and fluorescent signal amplification processes.

Before founding MultiplexDX, he was working at a premier cancer research organization - National Cancer Institute (NCI) for 4 years. Pavol is a PhD trained Nucleic Acid Chemist/Biochemist focusing on modified oligonucleotide synthesis and spectroscopic analysis of nucleic acid structure/function.

Pavol has 35+ scientific publications, is the inventor of 3 granted patents, and is a member of the Science Advisory Board of the Slovakian Ministry of Health. Pavol is a member of an exclusive network of CEOs called Mindshare and won several prestigious awards highlighting his business and scientific achievements.

Vladimir has been working over 10 years in the biotechnology industry, in positions ranging from scientist to Director of Business Development. He received his PhD in molecular biology from the University of Bern. For 6 years, Vladimir was a Visiting scientist at the National Cancer Institute, USA.

In 2004, he joined Trophogen as a Senior Scientist for the first time and then returned to the company in 2011 after a three year break. During his time at Trophogen, he advanced from scientist to Director of Business Development and, as such, played a pivotal role in securing licensing deals with Zoetis, the world’s largest animal health company. Before joining Trophogen for the second time, Vladimir worked as a Manufacturing scientist at the diagnostics company QIAGEN. He designed and implemented new manufacturing processes in compliance with CGMP regulations. He was also sponsored by QIAGEN to receive his MBA in Business Integration from the University of Wurzburg.

Vladimir has 20+ scientific publications.